Clinical Trial Update: DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a dendritic cell vaccine with IL-2 and interferon-alpha-2a in metastatic renal cell carcinoma. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Dendritic cell vaccine
• Interferon alpha-2a (interferon alfa-2a)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-06-10